US Stock MarketDetailed Quotes
BMEA Biomea Fusion
- 6.140
- +0.380+6.60%
Close Dec 11 16:00 ET
- 6.140
- 0.0000.00%
Post 20:02 ET
222.51MMarket Cap-1.53P/E (TTM)
6.440High5.680Low889.18KVolume5.680Open5.760Pre Close5.47MTurnover3.96%Turnover RatioLossP/E (Static)36.24MShares20.21052wk High2.93P/B137.87MFloat Cap3.61052wk Low--Dividend TTM22.46MShs Float43.690Historical High--Div YieldTTM13.19%Amplitude2.840Historical Low6.152Avg Price1Lot Size
Biomea Fusion Stock Forum
Sign in to post a comment
$Biomea Fusion (BMEA.US)$ Reuters· just
Biomea Fusion Announces Preliminary Data From Ongoing Covalent-103 Study of Investigational Covalent Flt3 Inhibitor Bmf-500 in Relapsed or Refractory Acute Leukemia
Biomea Fusion Announces Preliminary Data From Ongoing Covalent-103 Study of Investigational Covalent Flt3 Inhibitor Bmf-500 in Relapsed or Refractory Acute Leukemia
1
$Biomea Fusion (BMEA.US)$ wonder how they come out with such T.P?...![]()
1months from profit tanked to losses...
1months from profit tanked to losses...
4
10
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Biomea Fusion (BMEA.US)$ Reuters· 1 min ago
Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of GLP-1-Based Therapies
Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of GLP-1-Based Therapies
1
$Biomea Fusion (BMEA.US)$
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate hig...
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate hig...
4
1
1
$Biomea Fusion (BMEA.US)$ after hours could be interesting
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Trytosaveabit OP : Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia
BMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levels
Pharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetration
Preliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recovery (CRi) and reductions in bone marrow blasts in 5 of 6 of the evaluable FLT3 mutated patients